Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

News in the Life Sciences Industry

Results 8841 - 500 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25
Reset 

IV Bag Market to Witness Rapid Growth, Reaching $3.4B by 2034, as Healthcare Sector Evolves

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Global Clinical Alarm Management Market Analysis/Forecast Report 2023-2028: Gradual Shift of Accountability from Payers to Providers and Growing Demand for Value-Based Healthcare

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Contract Research Organization Services Market to Reach USD 129.8 Billion by 2029, Driven by Drug Development Initiatives and Precision Medicine Demand

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Global Venous Thromboembolism Treatment Market to Reach $4.40 Billion by 2030, as Demand for Minimally Invasive Procedures Grows

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

$10.5+ Bn Lab Automation Markets - Global Forecast to 2030: Increasing Focus on Food Quality and Safety, Rising Awareness & Growing Adoption of Personalized Medicines

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Change in Medivir's nomination committee before the 2024 AGM

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Medivir AB

The TIM Company Rebrands as InnoGI Technologies and Introduces the SurroGutâ„¢ Platform to Reshape Industry Norms and to Support FDA Modernization Act 2.0

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  The TIM Company

Colorectal cancer is the 2nd deadliest cancer in Canada, let's work together to avoid making it number one

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Colorectal Cancer Canada

GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  GlaxoSmithKline Inc., Canada | GlaxoSmithKline Inc.

Pharmascience Expands its Contract Development and Manufacturing Organization (CDMO) Services With a New Commercial Business Unit

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Pharmascience Inc.

Championing Rare Voices on Rare Disease Day

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Takeda Canada Inc.

Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Fusion Pharmaceuticals Inc.

HIGH Q TECHNOLOGIES SECURES $3.75 MILLION FROM GOVERNMENT OF CANADA TO SUPPORT EXPANSION OF PROTEIN MEASUREMENT PLATFORM FOR DRUG DISCOVERY

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Hitachi High-Technologies Canada, Inc. | High Q Technologies, Inc.

NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Alexion, AstraZeneca Rare Disease

JMIR NEUROTECHNOLOGY INVITES SUBMISSIONS ON BRAIN-COMPUTER INTERFACES (BCIS)

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024

Development Strategy for Early-Stage Assets: The Commercial-Clinical Handshake, Upcoming Webinar Hosted by Xtalks

Read more ››
By: PR Newswire Association LLC. - 26 Feb 2024
Related companies:  Xtalks

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Read more ››
By: GlobeNewswire - 26 Feb 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Read more ››
By: GlobeNewswire - 26 Feb 2024
Related companies:  Zealand Pharma A/S

Community Health Worker (CHW) Initiative Launched In New Hampshire

Read more ››
By: GlobeNewswire - 26 Feb 2024
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25
to the top ↑